Mounjaro (tirzepatide) is approved for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
It is suitable for those who have not achieved adequate control with other treatments. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as well as known hypersensitivity to tirzepatide or its excipients. Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disorders, or diabetic retinopathy. It is not for use in type 1 diabetes or pediatric patients. Women of reproductive potential should use non-oral contraceptives due to potential interactions with oral hormonal contraceptives. Always consult a healthcare provider to assess eligibility and monitor for side effects like pancreatitis or thyroid tumors.

